Qiagen (NYSE:QGEN) Issues FY 2026 Earnings Guidance

Qiagen (NYSE:QGEN) issued an update on its FY 2026 earnings guidance on Monday morning. The company provided EPS guidance of 2.430- for the period, compared to the consensus EPS estimate of 2.510. The company issued revenue guidance of $2.1 billion-$2.1 billion, compared to the consensus revenue estimate of $2.2 billion. Qiagen also updated its Q1 2026 guidance to 0.540-0.540 EPS.

Wall Street Analyst Weigh In

QGEN has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft upgraded Qiagen from a “hold” rating to a “buy” rating and set a $54.00 price target for the company in a research note on Friday, March 13th. Weiss Ratings restated a “hold (c)” rating on shares of Qiagen in a research note on Friday, March 27th. Stifel Nicolaus set a $50.00 price objective on shares of Qiagen and gave the company a “hold” rating in a report on Friday, February 6th. Zacks Research lowered shares of Qiagen from a “hold” rating to a “strong sell” rating in a research report on Monday, March 9th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Qiagen from $55.00 to $60.00 and gave the stock an “overweight” rating in a research note on Friday, February 6th. Four research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Qiagen has a consensus rating of “Hold” and a consensus target price of $53.64.

Qiagen Stock Performance

QGEN stock traded down $0.26 during midday trading on Monday, reaching $38.15. The stock had a trading volume of 1,473,493 shares, compared to its average volume of 2,228,451. The stock has a market cap of $7.86 billion, a PE ratio of 18.92, a P/E/G ratio of 1.99 and a beta of 0.79. The company has a debt-to-equity ratio of 0.44, a quick ratio of 3.31 and a current ratio of 3.90. The firm has a fifty day simple moving average of $42.91 and a two-hundred day simple moving average of $47.14. Qiagen has a 52-week low of $37.40 and a 52-week high of $57.81.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.61 by $0.01. The business had revenue of $540.42 million for the quarter, compared to the consensus estimate of $528.53 million. Qiagen had a return on equity of 14.56% and a net margin of 20.33%.The company’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.61 EPS. Qiagen has set its FY 2026 guidance at 2.500- EPS and its Q1 2026 guidance at 0.540- EPS. As a group, equities research analysts anticipate that Qiagen will post 2.5 EPS for the current year.

Hedge Funds Weigh In On Qiagen

A number of institutional investors have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD lifted its stake in Qiagen by 12.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 8,429,424 shares of the company’s stock valued at $379,072,000 after acquiring an additional 906,589 shares during the period. Amundi increased its stake in shares of Qiagen by 4.4% in the third quarter. Amundi now owns 4,290,273 shares of the company’s stock worth $201,471,000 after acquiring an additional 181,509 shares during the period. Boston Partners acquired a new stake in shares of Qiagen in the third quarter worth $179,450,000. Sei Investments Co. raised its holdings in shares of Qiagen by 5.0% during the third quarter. Sei Investments Co. now owns 1,902,296 shares of the company’s stock worth $84,995,000 after purchasing an additional 90,294 shares during the last quarter. Finally, Barclays PLC raised its holdings in shares of Qiagen by 41.7% during the fourth quarter. Barclays PLC now owns 1,539,762 shares of the company’s stock worth $69,243,000 after purchasing an additional 452,831 shares during the last quarter. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.